The Forces Behind Cell Movement od Revathi Ananthakrishnan, Allen Ehrlicher

Polni tekst

Pharmacological modeling and biostatistical analysis of a new drug od Revathi Ananthakrishnan, Philimon Gona

Polni tekst

2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy od Revathi Ananthakrishnan, Stephanie Green, Daniel Li, Michael LaValley

Polni tekst

An overview of the BOIN design and its current extensions for novel early-phase oncology trials od Revathi Ananthakrishnan, Ruitao Lin, Chunsheng He, Yanping Chen, Daniel Li, Michael LaValley

Polni tekst

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma od Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano‐Mori, Daisuke Kaji, Revathi Ananthakrishnan, Ken Ogasawara, Lara Stepan, Claudia Schusterbauer, Nils Rettby, Jens Hasskarl, Koji Izutsu

Polni tekst

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study od Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani

Polni tekst